Key result
BioGlue use in CABG is linked to fibrotic graft stenosis requiring re-do surgery.
Why the study?
The use of albumin cross-linked glutaraldehyde (BioGlue) as a hemostatic agent may cause early stenosis of coronary artery bypass grafts, but this complication is not well documented.
Case Report (n=1)
BioGlue application during CABG may be associated with fibrotic narrowing and stenosis of bypass grafts, necessitating judicious use.
May warrant caution with BioGlue in CABG; single case leaves open need for confirmatory studies.
Bioglue which constitutes albumin cross linked with glutaraldehyde (ACLG) produced by Cryolife, Inc, Kennesaw, GA was introduced as a better alternative to GRF glue with less tissue necrosis. We report a case of a 69-year-old male who developed stenosis of his saphenous vein and internal thoracic artery bypass grafts, requiring re-do coronary artery bypass grafting. Both fibrotic narrowing were in close proximity to the site of Bioglue application and appears to be a reaction to the glue. The advent of ACLG has facilitated surgery; however, this case highlights a potential side effect, emphasizing the judicious use of this hemostatic agent in patients.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2011) conducted a case report in Coronary artery bypass graft stenosis (n=1). BioGlue (albumin cross-linked with glutaraldehyde) was evaluated on Graft stenosis requiring re-do CABG. Application of BioGlue during coronary artery bypass grafting was associated with fibrotic narrowing and stenosis of bypass grafts requiring re-do surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: